Virtual Library

Start Your Search

K. Sugio



Author of

  • +

    P1.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 224)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
    • Presentations: 1
    • +

      P1.08-034 - The Clinicopathological Significance of PD-L1 Expression in Thymoma (ID 1572)

      09:30 - 17:00  |  Author(s): K. Sugio

      • Abstract
      • Slides

      Background:
      Programmed Death Ligand 1 (PD-L1) is an immune checkpoint molecule that binds to the PD-1 receptor, thereby suppressing the activity of tumor infiltrating cytotoxic T cells. On the other hand, the immune checkpoint inhibitors (PD-L1, PD-1, CTLA-4) are notorious for causing autoimmune disorders. Ipilimab, an anti-CTLA-4 antibody, and nivolumab, an anti-PD-1 antibody, have been shown to induce myasthenia gravis (MG) in clinical trials. Although it has been hypothesized that the binding of PD-L1 to PD-1 is essential for T cell maturation, the role of PD-L1 in thymoma and autoimmune disorders remains unclear.

      Methods:
      We studied 52 consecutive patients who underwent resection for thymoma in our institution from 1995 to 2013. The median age of the 52 patients was 59 years (range: 21-77), 46% were male, and 31%, 52% and 15% corresponded to the WHO types of A or AB, B1 or B2, and B3, respectively. Thirty-five percent of the patients had MG, and 23% had advanced disease (Masaoka stage IV). Formalin-fixed paraffin embedded tissue sections were stained with PD-L1 rabbit monoclonal antibody (Cell Signaling Technology). The PD-L1 staining scores were calculated by multiplying the staining intensity (0: negative to 3: strong) of the membrane / cytoplasm in the tumor cell by the proportion of stained tumor cells. The staining score, WHO classification, Masaoka stage and the coexistence of MG were compared using the Mann-Whitney U -test.

      Results:
      The mean PD-L1 score was 45 (range: 0-300). The PD-L1 scores were higher in patients with more advanced disease (Masaoka stage IV; median 60, range 10-300) than in those with localized disease (Masaoka stage I-III; median, 20; range 0-160; p=0.047). Furthermore, the score was also related with the WHO classification; it was high in WHO type B3 patients (median, 60; range, 10-300), despite the fact that it remained low among types A, AB, B1 and B2 (median 20, range 0-160, p=0.033). There was no statistically significant association between the presence of MG and a high PD-L1 score.

      Conclusion:
      PD-L1 was highly expressed in more aggressive and advanced stages of thymoma. No prior studies have so far reported the significance of the PD-L1 expression on thymoma. Further studies are warranted to utilize immune checkpoint targeting therapies for thymoma.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.